EarningsQ2 2026 Earnings Report
MX:GMED Q2 2026 EPS Results
Actual EPS$25.17
Consensus EPS$20.65
Beat/MissBeat by +$4.53
One Year Ago EPS$16.16
MX:GMED Q2 2026 Revenue Results
Actual Revenue$14.83B
Expected Revenue$14.71B
Beat/MissBeat by +$126.47M
YoY Revenue Growth+5.94%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:GMED Upcoming Earnings
Globus Medical's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:GMED Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.Company Guidance
Top-Line Growth and Revenue Mix
Q2 revenue of $789.6M, up 6% as reported; excluding Nevro, base business growth was 9%. Musculoskeletal sales were $763.5M, up 8% YoY and 4% sequentially. Base business Globus sales were $708.6M, up 8.9% as reported (9% day-adjusted).
Strong Organic Spine Performance
U.S. Spine grew ~7% (7.3% reported) driven by procedural volume, competitive recruiting and new product pull-through. International Spine grew 14% as reported (12% constant currency), with double-digit growth across EMEA, APAC and LATAM.
Margin Expansion and Profitability
Adjusted gross profit margin expanded to 69.4% (up 200 bps YoY). Adjusted EBITDA margin reached 35.4% vs 28% prior-year quarter. Q2 fully diluted non-GAAP EPS was $1.34, up ~56% YoY (55.8% reported). GAAP net income was $151.6M ($1.10 GAAP EPS).
Trauma and Product Momentum
Trauma revenue increased 31% YoY and 18% sequentially. Trauma and neuromonitoring each grew over 30% and have four straight quarters of double-digit sales growth. Launched 3 products in Q2 (AUTOBAHN Hip fastener, TENSOR suture button system, RELINE ONE) and received 510(k) clearance for SCRIPT patient-specific spacers and rods (expected Q3 launch).
Robotics & Enabling Tech Adoption Indicators
Robotic utilization continues to expand with over 137,000 procedures performed. EGPS and eHub units deployed (sold, leased or rented) grew 11% sequentially and 25% YoY, validating demand for Excelsius technology despite near-term revenue mix shifts.
Cash Generation and Capital Allocation
Cash, cash equivalents and marketable securities of $840.5M at 6/30 vs $629.1M at 12/31. Operating cash flow of $412.1M in H1 2026. Repurchased $136.1M (1.6M shares) in Q2; $747M repurchased since NuVasive close, buying back 11.9M shares (~30% of merger dilution).
Raised EPS Guidance with Revenue Reaffirmation
Reaffirmed full-year revenue guidance of $3.18B–$3.22B (implying 8.2%–9.6% growth) and increased full-year non-GAAP EPS guidance to $4.95–$5.05 (implying 24.4%–26.9% growth over 2025).
Cost & Efficiency Progress
SG&A fell to $286.8M (36.3% of sales) from $303.6M (40.7% prior year) driven by synergy capture; R&D in Q2 was $36.3M (4.6% of sales) with planned ramp to 5%–6% for full-year 2026. Company reiterated target to return to mid-70s adjusted gross margin (expected entry into low-70s by year-end and mid-70s in ~2027).
MX:GMED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed